Randomized trial · people
Thymogen (IM862): 36% major responses in AIDS-related Kaposi's sarcoma
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This early human trial links the Glu-Trp dipeptide, given as IM862 nose drops, to tumor responses and mild side effects in AIDS-related Kaposi's sarcoma, but it lacked a placebo comparison, and a later placebo-controlled trial found IM862 no better than placebo.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2000
- Journal
- J Clin Oncol
What they tested
The team tested whether IM862, a natural peptide the authors describe as blocking new blood vessel growth, given as nose drops, was tolerable and had any effect on Kaposi's sarcoma tied to AIDS.
How the study was done
A randomized phase II trial in adults with AIDS-related Kaposi's sarcoma, almost all of them men, compared two schedules of 5 mg nasal drops: 5 days on and 5 days off (18 patients) or every other day (26 patients), with no placebo group. Treatment ran in cycles until the disease grew or side effects became too much, and 75% had already had chemotherapy.

What they found
Among the patients, 36% had a major response: 5 had a complete remission (tumors cleared) and 11 a partial remission (tumors shrank). Responses showed up after a median of 6 weeks and lasted a median of 33+ weeks, ranging from 12+ to 95+ weeks. Other patients had stable disease for 7 to 72+ weeks. Side effects were mild, short-lived headache, fatigue, tingling and nausea, with no blood-related side effects tied to treatment.
What it doesn’t show
This was a small trial with no placebo or untreated group, so it can't show how much of the effect came from IM862 itself. All but 5 patients were also taking protease inhibitors at the same time. A later, larger placebo-controlled trial of IM862 in the same disease found it no better than placebo.
The paper
Tulpule et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000.
The compound
More studies on Thymogen
- Thymogen (IM862): 8 of 25 kidney cancer patients had stable diseaseClinical trial · people · 2004
- Every study on Thymogen
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.